A recent trial enrolled ACS patients with previous myocardial infarction according to baseline serum levels of the inflammatory marker C-reactive protein ≥2 mg/L, which had been previously shown to predict adverse outcomes [28]. This evidence concerns the gene CRP and myocardial infarction.